NASDAQ:AQB - Aquabounty Technologies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.19 +0.03 (+1.39 %)
(As of 03/26/2019 02:48 PM ET)
Previous Close$2.16
Today's Range$2.19 - $2.21
52-Week Range$1.51 - $5.45
Volume603 shs
Average Volume766,204 shs
Market Capitalization$40.91 million
P/E Ratio-2.33
Dividend YieldN/A
AquaBounty Technologies, Inc., a biotechnology company, develops and markets products to enhance productivity in aquaculture. It offers AquAdvantage Salmon, a genetically modified Atlantic salmon for human consumption. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was founded in 1991 and is headquartered in Maynard, Massachusetts. AquaBounty Technologies, Inc. is a subsidiary of Intrexon Corporation.

Receive AQB News and Ratings via Email

Sign-up to receive the latest news and ratings for AQB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Fishing, hunting & trapping
Current SymbolNASDAQ:AQB



Sales & Book Value

Annual Sales$90,000.00
Book Value$1.54 per share


Net Income$-10,380,000.00
Net Margins-12,214.12%


Market Cap$40.91 million
Next Earnings Date5/14/2019 (Estimated)
OptionableNot Optionable

Aquabounty Technologies (NASDAQ:AQB) Frequently Asked Questions

What is Aquabounty Technologies' stock symbol?

Aquabounty Technologies trades on the NASDAQ under the ticker symbol "AQB."

How were Aquabounty Technologies' earnings last quarter?

Aquabounty Technologies Inc (NASDAQ:AQB) announced its quarterly earnings results on Thursday, March, 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.09. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.12 million. Aquabounty Technologies had a negative return on equity of 43.63% and a negative net margin of 12,214.12%. View Aquabounty Technologies' Earnings History.

When is Aquabounty Technologies' next earnings date?

Aquabounty Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Aquabounty Technologies.

What price target have analysts set for AQB?

2 brokers have issued twelve-month target prices for Aquabounty Technologies' shares. Their predictions range from $4.00 to $5.50. On average, they expect Aquabounty Technologies' stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 116.9% from the stock's current price. View Analyst Price Targets for Aquabounty Technologies.

What is the consensus analysts' recommendation for Aquabounty Technologies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquabounty Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aquabounty Technologies.

What are Wall Street analysts saying about Aquabounty Technologies stock?

Here are some recent quotes from research analysts about Aquabounty Technologies stock:
  • 1. According to Zacks Investment Research, "AquaBounty Technologies, Inc. is a biotechnology company. It focused on enhancing productivity in aquaculture. The company operates primarily in Maynard, Massachusetts and Fortune, Prince Edward Island. AquaBounty Technologies, Inc. is based in Maynard, United States. " (3/20/2019)
  • 2. National Securities analysts commented, "Upending Economics Of Land-Based Aquaculture. While the economics of ocean-based aquaculture is compelling, the scale required for land-based systems has historically prevented large-scale production of species like salmon. We believe AquaBounty’s AquAdvatage Salmon changes this dynamic and represents a truly disruptive technology.
     Final Regulatory Hurdle Nearly Cleared. In December, the USDA issued labeling guidance, which represented one of the final regulatory challenges in advance of domestic commercialization. We expect FDA labeling guidance in the coming months, at which point domestic production could begin.
     Establishing Pole Position. Both the local approval and construction of land-based systems, as well as the development and regulatory approval for growth enhanced species can take a decade or more. With both processes almost complete, we believe AQB has a first mover advantage with the potential to establish market share for the next decade before meaningful competition can arrive.
     High Ceiling Value. Once production begins, commercialization efforts can begin in full force. Should demand arise beyond our targeted production, several high margin strategies for expansion in both domestic and international markets could exist, in our opinion. Should this occur, we believe there is potential for shareholder value to meaningfully exceed current levels." (3/6/2019)

Has Aquabounty Technologies been receiving favorable news coverage?

News headlines about AQB stock have been trending somewhat positive on Tuesday, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aquabounty Technologies earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near term.

Who are some of Aquabounty Technologies' key competitors?

What other stocks do shareholders of Aquabounty Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquabounty Technologies investors own include Intrexon (XON), Celldex Therapeutics (CLDX), Rigel Pharmaceuticals (RIGL), Aurora Cannabis (ACB), ZIOPHARM Oncology (ZIOP), Ocular Therapeutix (OCUL), Verastem (VSTM), Allena Pharmaceuticals (ALNA), Fibrocell Science (FCSC) and Iovance Biotherapeutics (IOVA).

Who are Aquabounty Technologies' key executives?

Aquabounty Technologies' management team includes the folowing people:
  • Mr. David A. Frank, CFO & Treasurer (Age 59)
  • Dr. Ronald L. Stotish, Exec. Director (Age 70)
  • Mr. Alejandro Rojas, Chief Operating Officer of Aquabounty Farms (Age 57)
  • Ms. Sylvia Wulf, CEO, Pres & Director (Age 61)
  • Mr. Christopher H. Martin, Gen. Counsel & Company Sec. (Age 53)

Who are Aquabounty Technologies' major shareholders?

Aquabounty Technologies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Third Security LLC (60.11%), Actinver Wealth Management Inc. (0.22%) and PFG Advisors (0.09%). View Institutional Ownership Trends for Aquabounty Technologies.

Which major investors are buying Aquabounty Technologies stock?

AQB stock was bought by a variety of institutional investors in the last quarter, including Third Security LLC, Actinver Wealth Management Inc. and PFG Advisors. View Insider Buying and Selling for Aquabounty Technologies.

How do I buy shares of Aquabounty Technologies?

Shares of AQB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aquabounty Technologies' stock price today?

One share of AQB stock can currently be purchased for approximately $2.19.

How big of a company is Aquabounty Technologies?

Aquabounty Technologies has a market capitalization of $40.91 million and generates $90,000.00 in revenue each year. The company earns $-10,380,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis.

What is Aquabounty Technologies' official website?

The official website for Aquabounty Technologies is

How can I contact Aquabounty Technologies?

Aquabounty Technologies' mailing address is 2 MILL & MAIN PLACE SUITE 395, MAYNARD MA, 01754. The company can be reached via phone at 978-648-6000 or via email at [email protected]

MarketBeat Community Rating for Aquabounty Technologies (NASDAQ AQB)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  118 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about Aquabounty Technologies and other stocks. Vote "Outperform" if you believe AQB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by Staff

Featured Article: Institutional Investors

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel